Merck’s Arcoxia “Approvable” At FDA

The agency is seeking additional safety and efficacy data for the COX-2 inhibitor, the company says. Merck is working with international regulatory agencies on labeling changes for Arcoxia to address safety issues prompted by the Vioxx withdrawal.